Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II/III IDH-mutant astrocytomas

Neuro Oncol. 2019 Jun 10;21(6):819-821. doi: 10.1093/neuonc/noz052.

Authors

Patrick J Cimino¹, Eric C Holland²

Affiliations

¹ Department of Pathology, Division of Neuropathology, University of Washington School of Medicine, Seattle, Washington.
² Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington.

No abstract available

Keywords: IDH; astrocytoma; biomarkers; isocitrate dehydrogenase; molecular profiling.

Publication types

Comparative Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Astrocytoma / genetics
Astrocytoma / mortality*
Astrocytoma / pathology
Biomarkers, Tumor / genetics*
Brain Neoplasms / genetics
Brain Neoplasms / mortality*
Brain Neoplasms / pathology
Cohort Studies
DNA Copy Number Variations*
Humans
Isocitrate Dehydrogenase / genetics
Mutation*
Neoplasm Grading
Survival Rate
World Health Organization

Substances

Biomarkers, Tumor
IDH2 protein, human
Isocitrate Dehydrogenase
IDH1 protein, human